Report Viewer

NINDS CDE Notice of Copyright
Individualized%20Neuromuscular%20Quality%20of%20Life%20Questionnaire%20(INQoL)
Availability
For information on this form please follow this link:
Classification
Supplemental: Facioscapulohumeral muscular dystrophy (FSHD) and Myotonic Dystrophy (DM)
Short Description of Instrument

INQoL was orignally validated for muscle diease and myotonic disorders. In its current version it has also been use for Myasthenia Gravis. There are versions with additional symptom impact scores for diplopia, ptosis and dysphagia undergoiung evaluation at the moment. The Individualized Neuromuscular Quality of Life questionnaire (INQoL) consists of 45 questions within 10 sections.This is a neuromuscular disease specific quality of life measure for adults.
Scoring
There are a total of 45 items divided into 10 domains: 4 symptom impact domains, 5 life domains, 1 treatment impact domain.
 
A total score is calculated and ranges from 0=worse to 100=better
 
Sub-scores are calculated for each of the domains:
 
4 symptom impact scores for weakness, fatigue, pain and locking (myotonia); 0 = worse to 100 = better
 
5 QoL domain scores for 0 = worse to 100 = better
 
1 overall QoL score; 0 = worse to 100 = better
 
2 treatment effect scores (positive and negative); 0 = worse to 100 = better
Rationale/Justification
Administration Time: 20 minutes
References
Rose M, Brooks V, Walburn J, Sanders D, Pandya S, Kissel J et al. Validation of a quality of life measure for myasthenia gravis. Neuromuscular Disorders 2006; 16 supplement: S152 (Abstract).
 
Rose M, Brooks V, Walburn J, Sanders D, Pandya S, Kissel J et al. Validation of the UK Individualised Neuromuscular Quality of Life measure for use in the USA. Neuromuscular Disorders 2006; 16 supplement: S176 (Abstract).
 
Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology, March 2007 (In Press).
 
Document last updated November 2022